

GlucoTrack, Inc. (GCTK)



Company Overview

GlucoTrack is a medical device company developing a fully implantable continuous blood glucose monitor. The device is designed to sit inside the body for about three years and measure glucose directly from the blood. This approach removes the need for skin-worn sensors and frequent replacements. The company is now moving from early testing into longer human studies and preparing for future regulatory steps.



Key Highlights

- The system is fully implantable with no wearable device, removing a major pain point for patients.
- Designed for a three-year sensor life, far longer than today's 7–14 day skin sensors.
- Measures glucose directly from blood, which may improve accuracy.
- Completed animal studies, first-in-human data, and started a long-term study in Australia.
- IDE submission to the FDA is planned for Spring 2026.
- Endocrinologist survey showed 73% would prescribe the device if it lasts three years.
- Exploring new uses like epidural glucose monitoring for painful diabetic neuropathy.

Market Opportunity

Diabetes affects hundreds of millions of adults worldwide, and the number keeps rising. The continuous glucose monitoring market is already worth more than \$10 billion and is expected to reach up to \$50 billion in the next decade. The implantable CGM market is growing even faster as patients want longer-lasting, less visible devices. GlucoTrack aims to serve people who want better accuracy and fewer device changes. If successful, the company could compete in a large market where long-life sensors can command premium pricing.

Competitive Positioning

GlucoTrack stands out by offering a fully implantable, long-life sensor instead of a skin patch. The company aims to provide higher accuracy and ease of use, which may appeal to people frustrated with current CGMs. Its early clinical data, expert advisors, and work on epidural glucose sensing give it a unique angle that larger competitors do not focus on today. This combination could help GlucoTrack carve out a specialized niche in diabetes and neuromodulation.

Financial Snapshot & Traction

Pre-revenue as of Q3 2025	Device still in development.
Q3 2025 net loss	\$4.2M, improved from \$5.1M in Q3 2024.
First nine months of 2025 net loss	\$15.8M, up from \$12.5M in 2024.
Cash as of Sept 30, 2025	\$7.9M, up from \$5.6M at year-end 2024.
Added financings	\$3M from a note purchase, \$3.6M convertible note, and a \$20M equity line.
Clinical progress	First-in-human trial complete; Australian feasibility study underway.